Treatment of anemia in inflammatory bowel disease- systematic review and meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Avnit, Tomer ^b   Bieber, Amir ^a,b   Steinmetz, Tali ^a,b   Leibovici, Leonard ^a,b   Gafter Gvili, Anat ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON POLYMALTOSE; IRON SACCHARATE; MALTOFER; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; SYSTEMATIC REVIEW; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

ANEMIA; DATABASES, FACTUAL; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891619733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075540     Document Type: Article

References (47)

1. Gasche C (2000) Complications of inflammatory bowel disease. Hepatogastroenterology 47: 49-56.
2. Gasche C, Lomer MC, Cavill I, Weiss G (2004) Iron, anaemia, and inflammatory bowel diseases. Gut 53: 1190-1197.
3. Ohira Y, Edgerton VR, Gardner GW, Senewiratne B, Barnard RJ, et al. (1979) Work capacity, heart rate and blood lactate responses to iron treatment. Br J Haematol 41: 365-372.
4. Wells CW, Lewis S, Barton JR, Corbett S (2006) Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 12: 123-130.
5. Cucino C, Sonnenberg A (2001) Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis 7: 250-255.
6. Ebinger M, Leidl R, Thomas S, Von Tirpitz C, Reinshagen M, et al. (2004) Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol 19: 192-199.
7. Werlin SL, Grand RJ (1977) Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology 73: 828-832.
8. Gasche C, Reinisch W, Lochs H, Parsaei B, Bakos S, et al. (1994) Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 39: 1930-1934.
9. Horina JH, Petritsch W, Schmid CR, Reicht G, Wenzl H, et al. (1993) Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: results in three patients. Gastroenterology 104: 1828-1831.
10. Hoffbrand AV, Stewart JS, Booth CC, Mollin DL (1968) Folate deficiency in Crohn's disease: incidence, pathogenesis, and treatment. Br Med J 2: 71-75.
11. Taffet SL, Das KM (1983) Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 28: 833-842.
12. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA (1999) Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 230: 111-115.
13. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, et al. (2000) Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482.
14. Giannadaki E, Potamianos S, Roussomoustakaki M, Kyriakou D, Fragkiadakis N, et al. (1997) Autoimmune hemolytic anemia and positive Coombs test associated with ulcerative colitis. Am J Gastroenterol 92: 1872-1874.
15. Kulnigg S, Gasche C (2006) Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 24: 1507-1523.
16. Wilson A, Reyes E, Ofman J (2004) Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 116 Suppl 7A: 44S-49S.
17. Gasche C (2000) Anemia in IBD: the overlooked villain. Inflamm Bowel Dis 6: 142-150; discussion 151.
18. Higgins JPT GS, eds. (2011) Cochrane handbook for systematic reviews of interventions: version 5.1.0. Cochrane Collaboration.
19. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412.
20. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, et al. (1994) Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 106: 287-296.
21. Harvey RF, Bradshaw JM (1980) A simple index of Crohn's-disease activity. Lancet 1: 514.
22. Best WR, Becktel JM, Singleton JW, Kern F, Jr. (1976) Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444.
23. Walmsley RS, Ayres RC, Pounder RE, Allan RN (1998) A simple clinical colitis activity index. Gut 43: 29-32.
24. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, et al. (2009) Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 44: 838-845.
25. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, et al. (2008) A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 103: 1182-1192.
26. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, et al. (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59: 342-353.
27. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, et al. (2005) Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther 22: 831-838.
28. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, et al. (2005) Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 40: 1058-1065.
29. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, et al. (2011) FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 141: 846-853 e841-842.
30. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, et al. (1997) Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 126: 782-787.
31. Kulnigg-Dabsch S, SchmidW, Howaldt S, Stein J, Mickisch O, et al. (2013) Iron Deficiency Generates Secondary Thrombocytosis and Platelet Activation in IBD: the Randomized, Controlled ThromboVIT Trial. Inflamm Bowel Dis.
32. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, et al. (1996) Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 334: 619-623.
33. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, et al. (2005) Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 100: 2503-2509.
34. Moore RA, Gaskell H, Rose P, Allan J (2011) Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 11: 4.
35. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, et al. (2010) Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55: 535-548.
36. Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, et al. (2011) Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 161: 822-831 e822.
37. Lee TW, Kolber MR, Fedorak RN, van Zanten SV (2012) Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis 6: 267-275.
38. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, et al. (2008) Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 52: 897-906.
39. Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, et al. (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52: 18-29.
40. Avni T, Leibovici L, Gafter-Gvili A (2012) Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail 14: 423-429.
41. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, et al. (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12: CD003407.
42. Marti-Carvajal AJ, Agreda-Perez LH, Sola I, Simancas-Racines D (2013) Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev 2: CD000332.
43. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, et al. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914-924.
44. Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, et al. (2007) Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 13: 1545-1553.
45. Eccles M, Clapp Z, Grimshaw J, Adams PC, Higgins B, et al. (1996) North of England evidence based guidelines development project: methods of guideline development. BMJ 312: 760-762.
46. Biancone L, Pavia M, Del Vecchio Blanco G, D'Inca R, Castiglione F, et al. (2001) Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 7: 287-294.
47. Pizzi LT, Weston CM, Goldfarb NI, Moretti D, Cobb N, et al. (2006) Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 12: 47-52.